Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 28, 2026; 32(40): 120447
Published online Oct 28, 2026. doi: 10.3748/wjg.120447
Published online Oct 28, 2026. doi: 10.3748/wjg.120447
Baseline cytokines and programmed death-ligand 1 prognostic value in advanced gastric cancer with sintilimab plus chemotherapy
Yong-Cheng Li, Department of Medical Oncology, Xuzhou Central Hospital, Southeast University, Xuzhou 221009, Jiangsu Province, China
Di Pan, Hao-Nan Liu, Zi-Cheng Pei, Yu-Qi Li, Zheng-Xiang Han, Wen-Lou Liu, Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China
Co-first authors: Yong-Cheng Li and Di Pan.
Co-corresponding authors: Zheng-Xiang Han and Wen-Lou Liu.
Author contributions: Liu WL and Han ZX designed the study and they contribute equally to this study as co-corresponding authors; Li YC and Pan D contribute equally to this study as co-first authors; Liu HN, Pan D and Li YQ collected the clinical data and analyzed the data; Pan D, Li YQ and Liu WL wrote the paper; Liu WL, Pan D, Li YQ and Pei ZC revised the paper; all authors contributed to the article and approved the submitted version.
Institutional review board statement: The study protocol was reviewed and approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (Approval No. XYFY2024-KL408-01).
Informed consent statement: The requirement for written informed consent was waived by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University due to the retrospective nature of this study.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Data sharing statement: The data included in this study can be obtained from the corresponding author.
Corresponding author: Wen-Lou Liu, MD, PhD, Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, No. 99 Kunpeng Road, Economic and Technological Development Zone, Xuzhou 221000, Jiangsu Province, China. liuwenlou@163.com
Received: February 27, 2026
Revised: March 31, 2026
Accepted: April 21, 2026
Published online: October 28, 2026
Processing time: 197 Days and 15.3 Hours
Revised: March 31, 2026
Accepted: April 21, 2026
Published online: October 28, 2026
Processing time: 197 Days and 15.3 Hours
Core Tip
Core Tip: This study explores advanced gastric cancer (AGC) patients receiving first-line sintilimab plus chemotherapy, identifying baseline interleukin (IL)-6, IL-10, IL-17 and programmed death-ligand 1 as independent overall survival prognostic factors. A well-validated nomogram model is established, and these peripheral blood indices serve as novel biomarkers for screening AGC patients who benefit from immunotherapy.